From tariffs to trade deals: What the UK-US Pharma agreement means for Ireland’s Life Sciences sector

At the beginning of December, the US and the UK have signed a landmark agreement that could reshape the pharmaceutical and life sciences landscape for decades to come.

In this episode of our Life Sciences podcast, Yogan Patel, Head of Life Sciences, Pharma & MedTech at MHA, is joined by Brendan Murphy, Partner at Baker Tilly Ireland, and Andrew Thurston, Customs Manager at MHA. Together, they explore the potential impact of the recent Trump tariff announcements and this agreement on the sector.

With rumours that tariffs could reach unprecedented levels, global supply chains and pharmaceutical production face significant disruption.

They are discussing:

• What the agreement means for businesses on both sides of the Atlantic.
• How companies are adapting to the changing trade environment.
• Whether this marks the start of a new era for pharma or just the calm before the next storm.